News: SSRIs treat PMS/premenstrual dysphoric disorder
SSRIs effectively treat premenstrual symptoms.
Selective serotonin reuptake inhibitors (SSRIs) (i.e., citalopram, fluoxetine, paroxetine, and sertraline) effectively treat premenstrual symptoms, particularly with continuous dosing, but perhaps not as effectively as previously reported, according to the findings of a recent meta-analysis.
Researchers included 29 published double-blind, randomized controlled studies involving almost 3,000 women in their analysis.
Overall, they found SSRIs significantly effective for treating both PMS and premenstrual dysphoric disorder (OR, 0.40; 95% CI, 0.31–0.51). While no particular SSRI was more effective than another, continuous dosing regimens were more effective (OR, 0.28; 95% CI, 0.18–0.42) than intermittent ones (OR, 0.55; 95% CI, 0.45–0.68).
Shah NR, Jones JB, Aperi J, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol. 2008;111:1175-1182.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
